← Back to Screener
Apimeds Pharmaceuticals US, Inc. (APUS)
Price$1.88
Favorite Metrics
Price vs S&P 500 (26W)-89.35%
Price vs S&P 500 (4W)-83.40%
Market Capitalization$23.64M
All Metrics
Book Value / Share (Quarterly)$0.77
Price vs S&P 500 (YTD)-84.71%
10-Day Avg Trading Volume0.05M
EPS (Annual)$-0.12
ROI (Annual)-260.31%
Cash / Share (Quarterly)$0.69
ROA (Last FY)-10643.11%
Cash Flow / Share (Annual)$-0.06
P/B Ratio2.43x
P/B Ratio (Quarterly)2.27x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-11.10x
EPS Incl Extra (Annual)$-0.12
Current Ratio (Annual)0.01x
Quick Ratio (Quarterly)10.80x
3-Month Avg Trading Volume0.02M
52-Week High$40.31
EPS Excl Extra (Annual)$-0.12
26-Week Price Return-90.26%
Quick Ratio (Annual)0.00x
13-Week Price Return-88.54%
Total Debt / Equity (Annual)8.37x
Current Ratio (Quarterly)12.79x
Enterprise Value$15.408
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.00
3-Month Return Std Dev227.64%
ROE (Last FY)-2440.19%
EPS Basic Excl Extra (Annual)$-0.12
Total Debt / Equity (Quarterly)0.05x
Revenue / Share (Annual)$0.00
Year-to-Date Return-88.54%
5-Day Price Return-1.57%
EPS Normalized (Annual)$-0.12
Month-to-Date Return5.06%
EBITD / Share (Annual)$-0.11
LT Debt / Equity (Annual)8.37x
LT Debt / Equity (Quarterly)0.00x
Price vs S&P 500 (13W)-84.00%
Beta0.80x
52-Week Low$1.61
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
APUSApimeds Pharmaceuticals US, Inc. | — | — | — | — | $1.88 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Apimeds Pharmaceuticals is a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered bee venom-based therapy targeting inflammation and pain associated with osteoarthritis and multiple sclerosis. The company's lead candidate is already marketed in South Korea under the brand name Apitoxin for osteoarthritis treatment, providing clinical validation of the therapeutic approach.